Summarized by Masters of Longevity from Longevity Docs News.
News piece about a newly approved oral Parkinson’s medication, previewing clinical context, safety considerations, and anticipated availability.
Key Takeaways
- The FDA approved a once-daily selective D1/D5 dopamine agonist for Parkinson's disease with oral dosing.
- In TEMPO-3 the drug increased good on-time by 1.7 hours versus 0.6 hours for placebo without troublesome dyskinesia.
- Common adverse events included nausea, headache, dizziness, fatigue, and taste change; US launch is expected in October.
